Beactica is using its proprietary drug discovery platform to build a pipeline of novel small molecule inhibitors to address unmet medical needs. The prioritized programmes focus on epigenetic regulation of various cancer forms through the selective and reversible inhibition of lysine-specific histone demethylases (e.g. LSD1/KDM1A). Significant research shows that inhibitors of this enzyme class can be used for the treatment of several common cancers. Furthermore, these enzymes are also important in other diseases which could potentially give Beactica's compounds wider applications.
Beactica is actively seeking strategic collaborations with pharma and biotech companies for these discovery-stage assets.